BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10584060)

  • 1. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference.
    Mrowietz U; Christophers E; Altmeyer P
    Br J Dermatol; 1999 Sep; 141(3):424-9. PubMed ID: 10584060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of fumaric acid esters in psoriasis.
    Roll A; Reich K; Boer A
    Indian J Dermatol Venereol Leprol; 2007; 73(2):133-7. PubMed ID: 17456929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study.
    Mrowietz U; Christophers E; Altmeyer P
    Br J Dermatol; 1998 Mar; 138(3):456-60. PubMed ID: 9580799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.
    Dickel H; Bruckner T; Altmeyer P
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1710-1727. PubMed ID: 29705996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fumaric acid esters for psoriasis: a systematic review.
    Smith D
    Ir J Med Sci; 2017 Feb; 186(1):161-177. PubMed ID: 27271164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fumaric acid ester-induced T-cell lymphopenia in the real-life treatment of psoriasis.
    Dickel H; Bruckner T; Höxtermann S; Dickel B; Trinder E; Altmeyer P
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):893-905. PubMed ID: 30680823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis.
    Höxtermann S; Nüchel C; Altmeyer P
    Dermatology; 1998; 196(2):223-30. PubMed ID: 9568412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis.
    Hoefnagel JJ; Thio HB; Willemze R; Bouwes Bavinck JN
    Br J Dermatol; 2003 Aug; 149(2):363-9. PubMed ID: 12932244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
    Landeck L; Asadullah K; Amasuno A; Pau-Charles I; Mrowietz U
    Arch Dermatol Res; 2018 Aug; 310(6):475-483. PubMed ID: 29574575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
    Balasubramaniam P; Stevenson O; Berth-Jones J
    Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphopenia and CD4+/CD8+ Cell Reduction under Fumaric Acid Esters.
    Sondermann W; Rompoti N; Leister L; Huptas L; Klode J; Dissemond J; Körber A
    Dermatology; 2017; 233(4):295-302. PubMed ID: 28954274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus.
    Mrowietz U; Barker J; Boehncke WH; Iversen L; Kirby B; Naldi L; Reich K; Tanew A; van de Kerkhof PCM; Warren RB
    J Eur Acad Dermatol Venereol; 2018 Oct; 32 Suppl 3():3-14. PubMed ID: 30238510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Implications of Recent Recommendations for Managing Patients with Psoriasis Treated with Fumaric Acid Esters.
    Foley CC; Molloy OE; Lally A; Kirby B
    Dermatology; 2017; 233(2-3):175-177. PubMed ID: 28869956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteinuria with fumaric acid ester treatment for psoriasis.
    Ogilvie S; Lewis Jones S; Dawe R; Foerster J
    Clin Exp Dermatol; 2011 Aug; 36(6):632-4. PubMed ID: 21771009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case series of persistent lymphopaenia following treatment with fumaric acid esters for psoriasis.
    Beatty PE; Killion L; Callaghan G; Tierney E; Kelly G; Tobin AM
    J Clin Pharm Ther; 2021 Jun; 46(3):859-861. PubMed ID: 33432649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients].
    Altmeyer P; Hartwig R; Matthes U
    Hautarzt; 1996 Mar; 47(3):190-6. PubMed ID: 8647701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases.
    Harries MJ; Chalmers RJ; Griffiths CE
    Br J Dermatol; 2005 Sep; 153(3):549-51. PubMed ID: 16120141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the biomedical applications of fumaric acid and its ester derivatives: The multifaceted alternative therapeutics.
    Das RK; Brar SK; Verma M
    Pharmacol Rep; 2016 Apr; 68(2):404-14. PubMed ID: 26922546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fumaric acid esters.
    Rostami Yazdi M; Mrowietz U
    Clin Dermatol; 2008; 26(5):522-6. PubMed ID: 18755371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris.
    Gollnick H; Altmeyer P; Kaufmann R; Ring J; Christophers E; Pavel S; Ziegler J
    Dermatology; 2002; 205(1):46-53. PubMed ID: 12145434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.